CAMELOT FANTASIES

HTG Molecular Diagnostics
Shares in Arizona-based HTG Molecular Diagnostics Inc. recorded a trading volume of 1.14 million shares. The stock ended yesterday's trading session 4.00% higher at $4.16. The Company's shares have advanced 116.67% in the previous three months and 85.71% on an YTD basis. The stock is trading above its 200-day moving average by 45.92%. Furthermore, shares of HTG Molecular Diagnostics, which develops and markets products and services based on proprietary technology that facilitates the routine use of targeted molecular profiling, have an RSI of 46.92.
On May 04th, 2017, HTG Molecular Diagnostics announced that its new HTG EdgeSeq PATH Assay is expected to be available for research uses by the end of the second quarter of 2017. The HTG EdgeSeq PATH Assay has been designed for retrospective gene expression profiling to complement traditional immunohistochemistry testing by allowing investigators to assess mRNA expression of large numbers of biomarkers when formalin-fixed, paraffin-embedded sample availability is limited. Visit us today and download our complete research report on HTGM for free at: